Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
"ROCHE PRODUCTS (NEW ZEALAND) LIMITED, Biogen, Clinician",SMA treatments,People with SMA type II and III who are aged 19 years and over,SMA treatments (nusinersen (Spinraza) and risdiplam (Evrysdi)),Options for investment,Community and Hospital,Nervous System
